The maximal affinity of ligands.
Journal: 1999/October - Proceedings of the National Academy of Sciences of the United States of America
ISSN: 0027-8424
PUBMED: 10468550
Abstract:
We explore the question of what are the best ligands for macromolecular targets. A survey of experimental data on a large number of the strongest-binding ligands indicates that the free energy of binding increases with the number of nonhydrogen atoms with an initial slope of approximately -1.5 kcal/mol (1 cal = 4.18 J) per atom. For ligands that contain more than 15 nonhydrogen atoms, the free energy of binding increases very little with relative molecular mass. This nonlinearity is largely ascribed to nonthermodynamic factors. An analysis of the dominant interactions suggests that van der Waals interactions and hydrophobic effects provide a reasonable basis for understanding binding affinities across the entire set of ligands. Interesting outliers that bind unusually strongly on a per atom basis include metal ions, covalently attached ligands, and a few well known complexes such as biotin-avidin.
Relations:
Content
Citations
(153)
References
(38)
Chemicals
(3)
Processes
(4)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Proc Natl Acad Sci U S A 96(18): 9997-10002

The maximal affinity of ligands

Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94143-0446; and Johnson Research Foundation and Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104-6059
To whom reprint requests should be addressed. E-mail: ude.fscu.lgc@ztnuk.
Communicated by Larry Gold, NeXstar Pharmaceuticals, Inc., Boulder, CO
Communicated by Larry Gold, NeXstar Pharmaceuticals, Inc., Boulder, CO
Received 1998 Jun 15; Accepted 1999 Jul 1.

Abstract

We explore the question of what are the best ligands for macromolecular targets. A survey of experimental data on a large number of the strongest-binding ligands indicates that the free energy of binding increases with the number of nonhydrogen atoms with an initial slope of ≈−1.5 kcal/mol (1 cal = 4.18 J) per atom. For ligands that contain more than 15 nonhydrogen atoms, the free energy of binding increases very little with relative molecular mass. This nonlinearity is largely ascribed to nonthermodynamic factors. An analysis of the dominant interactions suggests that van der Waals interactions and hydrophobic effects provide a reasonable basis for understanding binding affinities across the entire set of ligands. Interesting outliers that bind unusually strongly on a per atom basis include metal ions, covalently attached ligands, and a few well known complexes such as biotin–avidin.

Abstract

Although an elegant analysis exists of the optimum kinetic performance of enzymes (1), estimation of maximal ligand binding has been addressed in a more limited way (2, 3). In this communication, we examine both empirical and theoretical bounds on the free energy of ligand binding. We conclude that maximal free-energy contributions per nonhydrogen atom are ≈−1.5 kcal/mol (1 cal = 4.18 J) across a wide variety of macromolecule–small molecule interactions. The empirical data also reveal a significant trend to smaller contributions per atom as the relative molecular mass of the ligand increases. These observations, drawn from a diverse collection of natural and synthetic ligands, can be used to guide drug-design strategies and explore evolutionary relationships. They also have implications for protein engineering and protein folding. Important exceptions to these generalizations are covalently bound ligands, interactions with metal ions, and a few interactions with small anions.

We begin our discussion with a summary of empirical equilibrium data on the free energy of ligand binding. We will assume, for convenience, the “biochemical” reference state: aqueous solutions at 300 K, pH = 7, all other concentrations at 1 M, although no effort has been made to correct the literature data. In Table Table1,1, we have collected dissociation constants or IC50 values of a diverse set of strongly bound ligands. These have been converted to ΔΔGbinding (Eq. 1) and are plotted against that number of nonhydrogen atoms per molecule in Fig. Fig.1.1.

equation M1
1

If we ignore simple cations and anions, the data show a sharp improvement in binding free energy until ≈15 heavy atoms per molecule. The ΔΔGbinding of the tightest-binding ligands then plateaus at ≈−15 kcal/mol (i.e., picomolar dissociation constants). The initial slope is approximately −1.5 kcal/mol per atom. We next plot the free energy of binding per heavy atom (ΔΔg) by dividing ΔΔG by the number of nonhydrogen atoms (Fig. (Fig.2).2). In displaying the data in this fashion, we are attributing the entire intermolecular interaction to the ligand, alone. This is a useful representation for our purposes because we do not always have the information required to identify interactions between specific atoms in the ligand and the target. Others have used the same presentation (4). It is immediately apparent (Table (Table1,1, Fig. Fig.2)2) that the largest binding interactions per atom are associated with metals, small anions, and ligands that form covalent bonds. The strongest nonmetallic complexes from natural or synthetic ligands do not exceed −1.5 kcal/mol complex per heavy atom. It is also clear from Fig. Fig.22 that there is a strong tendency for the contribution per atom to decrease as the number of atoms increase. The slope of this curve is ≈.01 kcal/mol per atom.

Table 1

Experimental binding affinities of selected ligands

No. of atomsLigandTargetType*−log K1Ref.
1Ca2+Amino transferaseIM6.705
1Hg2+Uroporphy synthaseIM6.005
1Mn2+Inositol phosphataseIM5.705
1Fe3+HydroxylaseIM5.305
1Ag+ArylformamidaseIM5.005
1FPhosphotransferaseIA4.555
1S2−PeroxidaseIA4.285
1XeMyoglobinL2.306
1NH3Meamine glutamate transferaseI1.795
2Carbon monoxideMyoglobinL7.527
2OxygenMyoglobinL6.187
2CyanideMethane oxygenaseIA6.005
2HydroxylamineGlycerol oxidaseIC5.925
3AzideGlycerol oxidaseIA5.705
3EthylamineProtease II3.005
4ThioacetamideMethane monooxygenI5.005
4NO3Carbonate deydrataseIA4.705
4VanadatePhytaseIA4.555
5ThiosemicarbazideMethane monooxygen.I6.005
5SO42−Creatine kinaseIA5.225
5IodoacetamideMethyl transferaseIC5.005
6PutrescineSpermine synthaseI8.775
6Aminooxyacetic acidAminotransferaseI7.195
6OxalateLactate dehydrogenaseIA5.805
7α-Aminobutyid acidNeuromanidase transmitterL8.002
7l-CysteineSerine acetyl transferaseI6.225
7AminomethiozolidineMethyl transferaseI5.405
8Muscimolα-aminobutylicacid agonistL8.732
8BromopyrimidoneCytosine deaminaseI6.245
8Phosphonoacetic acidDNA polymeraseI6.005
9AcetopyruvateAcetoacetate decarboxylaseI7.005
9Methyl iodotyrosineTyrosine monooxygenaseI6.305
9NitrooxazolidinoneAldehyde dehydrogenaseI5.465
9BenzamidineTrypsinI4.778
10AllopurinolXanthine oxidaseI9.172
10AcetylcholineCholinergic receptorL8.142
10CabacholCholinergic receptorL7.852
11Diethyl pyrocarbonateCa transmitterL8.805
11Dopamineα, β-androgen receptorL8.652
11Mercapto oxoglutaricIsocitrate dehydrogenaseI8.305
12NorepinephrineAdrenergic agonistL8.882
12NicotineNicotinic receptorL8.222
12Hydroxybenzyl-Me3NR4Acetycholiesterase II7.685
13Tiamenidineα-Adrenergic agonistL8.662
13Serotonin5-Hydroxy tryptamine receptorL8.309
13Benzyl mercaptopropionateCarboxypeptidaseI7.965
14Guanabenzα-Adrenergic receptorL9.022
14Methylenpenicillanicβ-LactamaseI8.855
14CaptoprilCarboxypeptidaseI8.705
15AminoclonidineL9.322
15Guanfacineα-Adrenergic agonistL8.732
15Isatin derivativeRhino proteaseI7.3010
16Acetophenone der.ACEsteraseIC14.8911
16BiotinStreptavidinL13.438
16NaphazolineAdrenergicL8.732
17MelatoninMelatonin receptorL8.9612
17Guanine derivativePurine nucleoside phosphorylaseI7.964
17piperoxanantihyper. receptorL7.852
18IodomelatoninMelanin receptorL10.6812
18Alprenololβ-adrenergic receptorL9.472
18PhosphoramidonMetalloproteinaseI7.555
19VesamicolVesamicol receptorL9.4713
19Propranololβ-adrenergic receptorL9.392
19Trimethoprim derDihydrofolate reductaseI8.5314
20EstradiolSteroid receptorL9.692
20Melatonin derivativeMelatonin receptorL9.6812
20Vesamicol derivativeVesamicol receptorL9.2013
212-Carboxyl arabinitol bisphosphateRibulose carboxylaseI12.7215
214-Carboxyl arabinitol bisphosphateRibulose carboxylaseI10.5515
21TriprolidineHistamine antagonistL9.982
21Trimethoprimdihydrofolate reductaseI8.442
22AmitriptylinoxideAntidepressantL9.022
22Mazindol derivativeDopamine transporterL8.8216
22Indolyl ethyl amines5-Hydroxy tryptamine receptorL8.4917
22Isatin derivativeRhino proteaseI8.0010
23Vesamicol der.VRL11.0513
23Neuraminic acid der.SialidaseI10.5218
23Melatonin der.melamin receptorL10.2412
23Vesamicol der.VRL10.1713
24Vesamicol der.VRL11.1913
24Isatin der.Rhino proteaseI8.7010
24MethadoneNarcoticL8.662
25Melatonin der.Melamin receptorL9.6212
25CorticosteroneSteroid receptorL8.512
25Isatin der.Rhino proteaseI8.4010
26AldosteroneSteroid receptorL9.322
26HaloperidolAntipsychoticL9.022
26Yohimbineα-2 adrenergic receptorL8.732
26Isatin der.Rhino proteaseI8.4010
27Vesamicol der.VRL9.7413
27DexetimideAnticholinergicL8.802
27DehydrosinefunginmRNA Me trans.I8.745
28Vesamicol der.VRL9.8213
28Indoyl ethyl amines5-Hydroxy tryptamine receptorL9.7017
28Prazosinα1-adrenergic agonistL9.622
29SpiperoneL10.272
29KetanserinSerotonin antagonistL9.392
29DextromoramideAnalgesicL9.022
30Peptide phosphonatesCarboxy peptidaseIM12.0019
30DomperidoneDopamine antagonistL10.132
30EtorphineNarcoticL9.912
31Carboxamide derivative5-Hydroxy tryptamine receptorL9.5420
31Benzodiazepine derivativeIntegrin antagonistL8.6021
31BudesonideGlucocorticoid receptorL8.5422
31Flavin mononucleotideCytochrome b reductaseI8.105
32Serotonin dimer5-Hydroxy tryptamine receptorL9.349
32Cyclic ureaHIV proteaseI8.8523
32Hoechst 33258DNAL7.4124
33MethotrexateDihydrofolate reductaseI9.708
34Cyclic-aza isostereHIV proteaseI10.2125
34BuprenorphinenarcoticL9.832
34PimozideantipsychoticL9.392
34Hoechst 33342DNAL7.4424
35Peptide phosphonatesCarboxypeptidaseIM11.5219
35ArgatrobanThrombinI7.728
35Peptide derivativeThermolysinI7.298
36Cyclic-aza isostereHIV proteaseI10.1525
36BenzodiazepinesIntegrinL8.5521
36Cyclic ureaHIV proteaseI8.3723
37Peptide phosphonatesCarboxypeptidaseIM11.4019
37Cyclic-aza isostereHIV proteaseI9.3125
37BenzodiazepinesIntegrinL8.8021
38HydroxypyroneHIV proteaseI10.2226
38Cyclic ureaHIV proteaseI9.9223
38BenzodiazepinesIntegrinL8.4021
39Cyclic sulfoneHIV proteaseI9.5227
39BenzodiazepinesIntegrinL7.0521
40Cyclic-aza isostereHIV proteaseI11.3025
40Hydroxy pyroneHIV proteaseI11.1626
41Peptide phosphonatesCarboxypeptidaseIM12.0019
41Cyclic ureaHIV proteaseI9.4823
41Cyclic sulfoneHIV proteaseI9.2227
42HydroxypyroneHIV proteaseI11.1026
42Cyclic ureaHIV proteaseI9.8523
43Peptide phosphonatesCarboxypeptidaseIM13.9619
43Cyclic ureaHIV proteaseI9.4823
43Cyclic sulfoneHIV proteaseI9.0027
44Cyclic ureaHIV proteaseI10.4128
45Serotonin dimer5-Hydroxy tryptamine receptorL10.059
46Cyclic ureaHIV proteaseI10.7528
46Cyclic ureaHIV proteaseI9.5123
47Zaragozic acid ASqualene synthaseI10.1129
48Cyclic ureaHIV proteaseI10.3528
50Cyclic ureaHIV proteaseI10.2028
50Hydroxyethyl amine derivativeCathepsin DI7.8530
51Zaragozic acid BSqualene synthaseI10.5429
51Combichem hydroxyethyl amine derivativeCathepsin DI8.0530
52Cyclic ureaHIV proteaseI9.3728
54Cyclic ureaHIV proteaseI10.5728
54Combichem hydroxyethyl amine derivativeCathepsin DI7.2330
55Peptide-basedThrombin receptorL7.4031
56Cyclic ureaHIV proteaseI10.3728
56Peptide-basedThrombin receptorL7.9231
58Cyclic ureaHIV proteaseI10.9628
60Cyclic ureaHIV proteaseI10.8028
62Cyclic ureaHIV proteaseI10.6228
64Cyclic ureaHIV proteaseI10.0728
64Acetyl-CoAAcetyl-CoA carboxylaseI8.005
67Peptide-basedThrombin receptorL8.1031
68Stearyl-CoAAcetyl-CoA carboxylaseI8.895

I, inhibitor; IM, metal ion inhibitor potential chelator in metalloprotein; IA, small anionic inhibitor; IC, potential covalent interaction; L, ligand (agonist or antagonist).

In most cases, Ki values were taken directly from the literature; however, some IC50 values have been used. Although the differences are small for purposes of this paper, original publications should be consulted for accurate thermodynamic data.
An external file that holds a picture, illustration, etc.
Object name is pq1792743001.jpg

Free energy of binding (in kcal/mol) for ligands and enzyme inhibitors plotted as a function of the number of nonhydrogen atoms in the ligand. See Table Table1.1. A line with slope of 1.5 kcal/mol and an intercept of 0 is included as a visual aid to analysis. ▵, Metal ions or metalloenzymes; ▴, small anions; ○, natural ligands; ●, enzyme inhibitors.

An external file that holds a picture, illustration, etc.
Object name is pq1792743002.jpg

Free energy of binding per atom (in cal/mol per atom) for ligands and enzyme inhibitors plotted as a function of the number of nonhydrogen atoms in the ligand. Symbols are as described in Fig. Fig.11.

Whereas there are certainly caveats concerning individual data points and uncertainties of reference state and experimental conditions, the empirical trends in the experimental data are clear. It is, however, much more difficult to establish limits based on theoretical grounds. Typical contributions to the free energy of binding include hydrogen bonding, the hydrophobic effect, van der Waals forces and electrostatic interactions (Eq 2; ref. 32).

equation M2
2

equation M3

Any such list is necessarily incomplete, and each term is a complex function of enthalpic and entropic factors so that decomposition in this way may have only heuristic value (32). Thus, we have elected to focus on the empirical free energy trends in Figs. Figs.11 and and22 and to compare them with theoretical estimates of important individual terms.

The interaction of two monovalent ions in van der Waals contact is −100 kcal/mol in vacuum or in crystals (33). This interaction is greatly diminished in water, leading to free energies of association near zero for ion pair formation. Many of the common ionizable groups in biological systems (e.g., guanidinium, carboxyl, phosphate) have the formal charge distributed across several heavy atoms. The contributions to overall affinity from electrostatic interactions are obviously important for small ligands where large affinities per atom are seen for the selective binding of small anions and cations. However, larger ligands generally have only a few formal charges per molecule, and the electrostatic groups in the binding region are increasingly buried and desolvated by the rest of the ligand. Thus, all things being equal, a given electrostatic interaction would provide a less favorable interaction in a larger ligand. Furthermore, many large, tight-binding ligands have no formal charges. Thus, although electrostatic interactions have a critical role to play in specific complexes, they do not, by themselves, offer a general explanation of the binding data.

We can estimate the maximum number of hydrogen bonds per molecule by using the number of polar atoms per total number of atoms. Whereas the fraction of polar atoms is quite high for a few small, tight complexes (e.g., biotin–avidin and carboxyl arabinitol bisphosphate/ribulose disphosphate carboxylase, Fig. Fig.2),2), for larger ligands, this fraction approaches 0.15–0.20, perhaps because of the need for a balanced composition to insure water/lipid solubilities (34). Furthermore, there are many examples among HIV protease inhibitors for which the affinity is poorly correlated with the number of hydrogen bonds (35). It seems unlikely that any simple accounting for the number of hydrogen bonds is broadly predictive of the strength of ligand–receptor complexes.

Instead, we suggest that the general behavior of ligand binding over this wide range of ligands is determined by a combination of van der Waals and hydrophobic interactions as well as by factors unrelated to the thermodynamics of binding.

Maximal contributions of van der Waals terms can be readily estimated on a very simple, solvent-free model. In this model, ligand and receptor atoms are arrayed on a cubic lattice of spacing dlat = 2 × r, where r is the van der Waals radius. The strongest interactions are for a single point ligand, well buried in “receptor” lattice. The model gives a maximal value of ≈8.5ɛ where ɛ is the well depth, typically ≈0.15 kcal for a front-row atom (36, 37), yielding ≈−1 kcal/mol per atom. As the number of ligand atoms increases, “self-shielding” reduces the average contribution per atom because of the strong r dependence of the force field. Limiting average interactions per atom are geometry-dependent: a completely buried long linear ligand gives a value of 6.5ɛ; a extended planar ligand ≈4ɛ, and a compact completely buried cubic ligand 3ɛ. If the ligand structure is only partially buried, smaller values are found. If we assume that the receptor site is preformed (3, 38), requiring no reorganization of either the site or the ligand, and we continue to ignore solvation, we can equate the full enthalpic term from the force field with the (maximal) free energy of interaction. Thus, van der Waals terms can yield substantial maximal interactions per atom that decrease as more atoms are added to the ligand. However, these maximal values are based on a vacuum reference state and might be significantly reduced with an aqueous reference state. It might be argued that desolvation terms should almost exactly compensate for ligand–receptor interactions, yielding little or no net binding. Two factors enhance ligand–receptor interactions compared with ligand–water interactions: the hydrophobic effect (see below) and the high atom density in macromolecules arising from polymer covalency. Protein densities, for example, are 30–40% higher than the density of water (39), leading to a 50–70% higher density of nonhydrogen atoms (based on an approximate protein empirical composition of C4NO). Effects of this size could readily yield significant net van der Waals contributions to the free energy of binding, even in the presence of strong ligand–solvent interactions. In addition, Myamoto and Kollman (38) have noted, on the basis of free energy calculations, that part of the hydrophobic effect arises from the repulsive van der Waals free energy of a nonpolar solute in water because of the larger contribution from the r than the r term.

Hydrophobic interactions can be estimated based on the (maximal) buried surface area or by converting free energy of transfers to a per heavy atom basis, yielding ≈850 cal⋅mol⋅carbon atom (40). This value is at the lower end of the range of the 25–75 cal/Å contribution for buried surface area—the subject of continued research activity (4143). If there were no site reorganization, these quantities would augment the van der Waals terms, leading to a limit of ≈−2 kcal⋅mol⋅heavy atom for the strongest interactions in a rigid, completely buried site. (38). Although these limits are consistent with experiment, the dependence on molecular size is less than is seen empirically in Figs. Figs.11 and and2.2. For simple ligand geometries, both van der Waals and hydrophobic terms should change in proportion to the surface/volume ratio. For simple geometries, the ratio reduces as n where n is the number of atoms, a smaller dependence than shown in Fig. Fig.22.

We conclude that a combination of van der Waals and hydrophobic terms provides the right magnitude to bound the experimental results, but the simplest models do not readily explain the nonlinearity of ligand interactions as a function of molecular size. Rather than exploring more complex models, we suggest that there are other reasons for this trend. Most of the data in Table Table11 are from natural ligands or synthetic enzyme inhibitors. Ligands that bind much more tightly than picomolar may be selected against either by nature or by the pharmaceutical industry for a number of reasons. First, the kinetic dissociation time of femtomolar ligands is measured in years (19)! Long ligand lifetimes might well have unintended consequences. Furthermore, issues of solubility, clearance, and the cost of analoging would also tend to limit the pursuit of tighter-binding ligands in the higher molecular weight range (44). Thus, it may be that very high affinity ligands are sought neither by nature nor by medicinal chemists. If so, the experimental data underrepresent maximal attainable affinities for large ligands.

I, inhibitor; IM, metal ion inhibitor potential chelator in metalloprotein; IA, small anionic inhibitor; IC, potential covalent interaction; L, ligand (agonist or antagonist).

Acknowledgments

We thank Jack Kirsch, Juan Alvarez and Geoff Skillman for helpful discussions. Research support from the National Institute of General Medical Sciences to I.D.K. and P.A.K. is gratefully acknowledged.

Acknowledgments

References

  • 1. Knowles J R. Nature (London) 1991;350:121.[PubMed]
  • 2. Andrews P R, Craik D J, Martin J L. J Med Chem. 1984;27:1648–1657.[PubMed]
  • 3. Miyamoto S, Kollman P A. Proc Natl Acad Sci USA. 1993;90:8402–8406.
  • 4. DeWitte R, Shakhnovich E. J Amer Chem Soc. 1996;118:11733–11744.[PubMed]
  • 5. Zollner H Handbook of Enzyme Inhibitors. Basel, Switzerland: Weinheim; 1989. [PubMed][Google Scholar]
  • 6. Ewing G J, Maestas S. J Phys Chem. 1970;74:2341–2344.[PubMed]
  • 7. Parkhurst L. Annu Rev Phys Chem. 1979;30:503–546.[PubMed]
  • 8. Rarey M, Kramer B, Lengauer T, Klebe G. J Mol Biol. 1996;261:470–4889.[PubMed]
  • 9. Halazy S, Perez M, Fourrier C, Pallard I, Pauwels P J, Palmier C, John G W, Valentin H-P, Bonnafous R, Martinez M. J Med Chem. 1996;39:4920–4927.[PubMed]
  • 10. Webber S E, Tikhe J, Worland S T, Fuhrman S A, Hendrickson T F, Matthews D A, Love R A, Patrick A K, Meador J W, Ferre R A, et al J Med Chem. 1996;39:5072–5082.[PubMed][Google Scholar]
  • 11. Nair H K, Lee K, Quinn D M. J Am Chem Soc. 1993;115:9939–9941.[PubMed]
  • 12. Spadoni G, Stankov B, Duranti A, Biella G, Lucini V, Salvatori A, Fraschini F. J Med Chem. 1993;36:4069–4074.[PubMed]
  • 13. Rogers G A, Kornreich W D, Hand K, Parsons S M. Mol Pharmacol. 1993;44:633–641.[PubMed]
  • 14. Dunn W J, III, Hopfinger A J, Catana C, Duraiswami C. J Med Chem. 1996;39:4825–4832.[PubMed]
  • 15. Schloss J V. J Biol Chem. 1988;263:4145–4150.[PubMed]
  • 16. Houlihan W J, Boja J W, Parrino V A, Kopajtic T, Kuhar M J. J Med Chem. 1996;39:4935–4941.[PubMed]
  • 17. Barf T A, Boer P d, Wikström H. J Med Chem. 1996;39:4717–4726.[PubMed]
  • 18. von Itzstein M, Dyason J C, Oliver S W, White H F, Wu W-Y, Kok G B, Pegg M S. J Med Chem. 1996;39:388–391.[PubMed]
  • 19. Kaplan A P, Bartlett P A. Biochemistry. 1991;30:8165–8170.[PubMed]
  • 20. Norman M H, Navas F, III, Thompson J B, Rigdon G C. J Med Chem. 1996;39:4692–4703.[PubMed]
  • 21. Samanen, J. M., Ali, F. E., Barton, L. S., Bondinell, W. E., Burgess, J. L., Callahan, J. F., Calvo, R. R., Chen, W., Chen, L., Erhard, K., et al. (1996) J. Med. Chem.39. [[PubMed]
  • 22. Ashton M J, Lawrence C, Karlsson J-A, Stuttle K A J, Newton C G, Vacher B Y J, Webber S, Withnall M J. J Med Chem. 1996;39:4888–4896.[PubMed]
  • 23. Lam P Y S, Ru Y, Jadhav P K, Aldrich P E, DeLucca G V, Eyermann C J, Chang C-H, Emmett G, Holler E R, Hodge C N, et al J Med Chem. 1996;39:3514–3525.[PubMed][Google Scholar]
  • 24. Harapanhalli R S, McLaughlin L W, Howell R W, Rao D V, Adelstein S J, Kassis A I. J Med Chem. 1996;39:4804.[PubMed]
  • 25. Sham H L, Zhao C, Stewart K D, Betebenner D A, Lin S, Park C H, Kong X-P, Kempf D J, Plattner J J, Norbeck D W, et al J Med Chem. 1996;39:392–397.[PubMed][Google Scholar]
  • 26. Thaisrivongs S, Skulnick H I, Turner S R, Strohbach J W, Tommasi R A, Johnson P D, Aristoff P A, Judge T M, Gammill R B, Watenpaugh K D, et al J Med Chem. 1996;39:4349–4352.[PubMed][Google Scholar]
  • 27. Kim C U, McGee L R, Krawczyk S H, Harwood E, Harada Y, Swaminathan S, Bischofberger N, Chen M S, Cherrington J M, Xiong S F, et al J Med Chem. 1996;39:3431–3434.[PubMed][Google Scholar]
  • 28. Wilkerson W W, Akamike E, Cheatham W W, Hollis A Y, Collins R D, DeLucca I, Lam P Y S, Ru Y. J Med Chem. 1996;39:4299–4312.[PubMed]
  • 29. Bergstrom J D, Kurtz M M, Rew D J, Amend A M, Karkas J D, Bostedor R G, Bansal V S, Dufresne C, VanMiddlesworth F L, Hensens O D, et al Proc Natl Acad Sci USA. 1993;90:80–84.[Google Scholar]
  • 30. Kick E K, Roe D C, Skillman A G, Liu G, Ewing T J A, Sun Y, Kuntz I D, Ellman J A. Chem Biol. 1997;4:297–307.[PubMed]
  • 31. Bernatowicz M S, E, Klimas C, Hartl K S, Peluso M, Allegretto N J, Seiler S M. J Med Chem. 1996;39:4879–4887.[PubMed]
  • 32. Dill K A. J Biol Chem. 1997;272:701–704.[PubMed]
  • 33. Atkins P W Physical Chemistry. San Francisco: Freeman; 1982. [PubMed][Google Scholar]
  • 34. Lipinski C A, Lombardo F, Dominy B W, Feeney P J. Adv Drug Del Rev. 1997;23:3–25.[PubMed]
  • 35. Holloway M, Wai J, Halgren T, Fitzgerald P, Vacca J, Dorsey B, Levin R, Thompson W, Chen L, deSolms S, et al J Med Chem. 1995;38:305–317.[PubMed][Google Scholar]
  • 36. Cornell W D, Cieplak P, Bayly C I, Gould I R, Kollman P A. J Amer Chem Soc. 1995;117:5179–5197.[PubMed]
  • 37. Kaminski G, Jorgensen W. J Phys Chem. 1997;100:18010–18013.[PubMed]
  • 38. Miyamoto S, Kollman P A. Proteins Struct Funct Genet. 1993;16:226.[PubMed]
  • 39. Kuntz I D, Crippen G M. Int J Peptide Protein Res. 1979;13:223–228.[PubMed]
  • 40. Tanford C The Hydrophobic Effect. New York: Wiley; 1973. , Chap. 2. [PubMed][Google Scholar]
  • 41. Dill K A. Science. 1990;250:297–298.[PubMed]
  • 42. Sharp K A, Nicholls A, Fine R F, Honig B. Science. 1991;252:106–109.[PubMed]
  • 43. Cheng Y-K, Rossky P J. Nature (London) 1998;392:696–698.[PubMed]
  • 44. Ajay, Walters W P, Murcko M A. J Med Chem. 1998;41:3314–3324.[PubMed]
  • 45. Katz B A, Clark J M, Finer-Moore J S, Jenkins T E, Johnson C R, Ross M J, Luong C, Moore W K, Stroud R M. Nature (London) 1998;391:608–612.[PubMed]
  • 46. Chong L T, Dempster S E, Hendsch Z S, Lee L-P, Tidor B. Protein Sci. 1998;7:206–210.
  • 47. Kim E, Baker C, Dwyer M, Murcko M A, Rao B G, Tung R D, Navia M A. J Am Chem Soc. 1995;117:1181–1182.[PubMed]
  • 48. Eisen M B, Wiley D C, Karplus M, Hubbard R H. Proteins. 1994;19:199–221.[PubMed]
  • 49. Bohacek R, McMartin C. J Am Chem Soc. 1994;116:5560–5571.[PubMed]
  • 50. Shuker S B, Hajduk P J, Meadows R P, Fesik S W. Science. 1996;274:1531–1534.[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.